Bioasis Technologies reports that the Japanese Patent Office has issued Japanese Patent No. 2019-189551 Notice of Allowance for the company’s xB3-IDS fusion proteins.
“We are excited about the acceptance of this patent by the Japanese Patent Office. It represents a major milestone for our intellectual property protection around our core assets for the delivery in the Lysosomal Storage Disease area in the important Asian market,” said Dr. Deborah Rathjen, Executive Chair of the Board of Bioasis.